KERX Financial Facts
Basic and diluted net loss per common share: -0.39Income taxes: 20K
See Full Income Statement
Accrued compensation and related liabilities: 4.92M
Total liabilities: 146.64M
See Full Balance Sheet
Keryx Biopharmaceuticals Inc. (KERX) Earnings
|
Expand Research on KERX
Next EPS Date | N/A | EPS Growth Rate | N/A |
---|---|---|---|
Average EPS % Beat Rate | -97.1% | Revenue Growth Rate | N/A |
Average % Move 1-Wk after EPS | -2.5% | Normal Earnings Time | Before Open |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
11/7/17 | Q317 | -$0.20 | -$0.18 | -$0.02 | $15M | $18.04M | = | Details | |||
2/7/18 | Q417 | -$0.26 | -$0.18 | -$0.08 | $18.7M | $17.53M | = | Details | |||
7/27/17 | Q217 | -$0.77 | -$0.18 | -$0.59 | $15.1M | $14.51M | = | Details | |||
5/4/17 | Q117 | -$0.21 | -$0.20 | -$0.01 | $11.8M | $10.27M | = | Details | |||
5/8/14 | Q114 | -$0.15 | -$0.08 | -$0.07 | $10M | $9.91M | N/A | Details | |||
8/1/16 | Q216 | -$0.42 | -$0.28 | -$0.14 | $9.3M | $8.6M | N/A | Details | |||
3/1/17 | Q416 | -$0.32 | -$0.25 | -$0.07 | $9.5M | $8.41M | = | Details | |||
4/28/16 | Q116 | -$0.39 | -$0.26 | -$0.13 | $6.8M | $6.63M | N/A | Details |